Antisense 2'-O-methylribooligonucleotides were targted ainst sp sequence elements in mutated human f-globin pre-mRNAs to restore correct splicing of these RNAs in vitro. The foflowing mutations of the P-globin gene, A G at nt 110 of the first intron (Pll(D), T -* G at nt 705 and C -T at nt 654 of the second intron (IVS275 and IVS204, respectively), which led toaberrant spcing of the corresponding pre-mRNAs, were previously identified as the underlying causes of hemIa. Aberrant splcing of pllo pre-mRNA was efficiently reversed by an olgonucleotide taeted aginst the branch point sequence in the first intron of the pre-mRNA but not by an oligonuceotide targeted against the aberrant 3' splice site. In both IVS27u and IVS26" pre-mRNAs, correct splicing was restored by oligonucleotides targeted apinst the aberrant 5' splice sites created by the mutations in the second intron or against a cryptic 3' splice site located upsteam and activated in the mutated backgrud. These experiments represent an approach in which antisense ogo tides are used to restore the f of a defective gene and not, as usual, to downregulate the expression of an underable gene.
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The potential of oligonucleotides as modulators of gene expression and as chemotherapeutic agents is currently under intense investigation. Rapidly accumulating literature has been surveyed in a number of recent reviews (1) (2) (3) (4) . The activity of antisense oligonucleotides generally relies on their hybridization with targeted RNA, leading either to its degradation by cellular RNase H orto a block in its translation (1) (2) (3) (4) . In another approach, so-called antigene oligonucleotides are directed against specific regions in DNA, where they form triplex structures and inhibit transcription by RNA polymerase 11 (5, 6) . Both antisense and antigene oligonucleotides lead to down-regulation oftargeted genes and are applied to reduce the intracellular level of undesirable gene products coded by viruses (7, 8) , other pathogens (9), or oncogenes (2) . This is difficult to accomplish, especially ifthe targeted gene codes for a protein that is stable and has a low turnover rate.
In the approach reported here, antisense oligonucleotides are designed to generate a correctgene product that had been rendered defective by mutations that changed the splicing pattern of the corresponding pre-mRNA. We have used oligonucleotides complementary to specific sequence elements in pre-mRNAs coded by mutated (-globin alleles identified in various cases of (-thalassemia. In this model system of potential clinical significance (10) , the oligonucleotides suppressed abenrant splicing pattern of ,B-globin pre-mRNA resulting from gene mutations and restored correct splicing.
MATERIALS AND METHODS
All pre-mRNAs were transcribed by SP6 RNA polymerase (11) from appropriate fragments of the human (-globin gene subcloned into the SP64 vector. HBA6 (12) virtually the entire second exon, the entire second intron, and a major portion ofthe third exon was subcloned into the SP64 vector. The resulting IVS2 clone was subsequently subjected to site-specific mutagenesis (14) . 18 ), in agreement with the markedly reduced levels of normal hemoglobin observed in patients with this form of thalassemia (10) . It was found that in (3"'O pre-mRNA the aberrant 3' splice site utilizes the normal branch point at nt 93 of the intron, competing with the correct 3' splice site and thereby reducing correct splicing (19) . Significantly for this work, mutations inactivating this element activate a cryptic branch point at nt 107 and result in splicing at the correct 3' splice site (20) . Aberrant splicing cannot proceed in the mutated background due to the proximity ofthe 3' splice site at position 110 to the cryptic branch point. We therefore reasoned that antisense oligonucleotides complementary to the normal branch point sequence will, like mutations, block its function in splicing and force the splicing machinery to select the cryptic branch point, generating correctly spliced mRNA.
To test this idea, a 14-mer 2'-O-methyloligonucleotide (oligonucleotide 1, Fig. 1 strated by the fact that at S ,uM an oligonucleotide targeted against the cryptic 3' splice site in the second intron of the (3-globin gene (oligonucleotide 3, Fig. 1 ; see also below) does not affect the original ratio of the spliced products (Fig. 2,  lane 7) . At higher concentrations (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) .M), oligonucleotide 1 inhibits splicing in an unspecific manner and generates greater amounts of an =240-nt RNA species, which is detectable in small quantities at a S jAM concentration of oligonucleotide 1 (Fig. 2, lane 6) . This product accumulates only in the presence of ATP and other components of the splicing mixture, and its length is consistent with cleavage of the RNA at the site of hybridization with the oligonucleotide. These results suggest the presence of an ATP-dependent nuclease that either recognizes RNA-2'-O-methyloligonucleotide duplexes and cleaves the RNA in an endonucleolytic manner or degrades RNA exonucleolytically and is blocked at the site of duplex formation.
The aberrant 3' splice site generated by the (3O mutation at position 111 appears to be an obvious target for reversal of aberrant splicing by an antisense oligonucleotide. Blocking this sequence element should be the simplest way of forcing the splicing machinery to use the original 3' splice site at the end of the intron. However, a 14-mer (oligonucleotide 2, Fig.  1 ) directed against the aberrant splice site, spanning nt 103-116 in the intron, was not effective; at increasing concentrations ofoligonucleotide 2, accumulation ofboth spliced products was inhibited; the correct one was inhibited somewhat more efficiently (Fig. 3, lanes 2-5) . Interestingly, the first step of the splicing reaction, cleavage at the 5' splice site and formation of the lariat-exon intermediate, seems to be less affected by oligonucleotide 2 than the formation of the final spliced product. This is shown by the presence of the intermediates generated during this step even at 5 and 10 ,uM concentrations of oligonucleotide 2 (Fig. 3, lanes 5 and 6) . At higher concentrations of the oligonucleotide, cleavage at the 5' splice site was also inhibited (data not shown).
The lack of success with oligonucleotide 2 may result from the proximity of the aberrant and correct 3' splice sites and, in consequence, the concomitant interference of this oligonucleotide with both splicing pathways. Note that in p110 pre-mRNA the sequence elements important for splicing (i.e., the two 3' splice sites, two branch point elements, and the polypyrimidine tract) are located within the stretch of 37 nt. Conceivably, hybridization of oligonucleotide 2 in the middle ofthis region interferes with binding of a large number of splicing factors assembling there and prevents any splicing by steric hindrance. Consistent with this idea, additional experiments showed that any oligonucleotide targeted downstream from the normal branch point and upstream from the correct 3' splice site inhibited splicing without restoring the correct pathway (results not shown). Note also that oligonucleotide 2, as well as some other oligonucleotides targeted to this region, block a significant portion of the polypyrimidine tract, which is essential for splicing.
Restoration of Correct Splicing In Intron 2 of the Human P-GIobin Gene. Whether an aberrant 3' splice site can nevertheless be used as a target for reversal of incorrect splicing was further tested on pre-mRNA carrying a T --G mutation at position 705 of the second intron of human 3-globin gene. This rare mutation (IVS2705), found in Mediterranean thalassemia patients (10, 16) , creates an additional, aberrant 5' splice site and activates a cryptic 3' splice site at position 579 of the intron (24) . The incorrect splicing pathway results in the removal of nt 1-578 and 706-850 as separate introns and incorporation of the remaining portion of the intron into the spliced product (Fig. 1) . In IVS2705 pre-mRNA the distances between each of the sequence elements involved in splicing exceed 100 nt, and no steric hindrance effects caused by the oligonucleotide would be expected. The control transcript (IVS2) containing the second intron of normal ,B-globin pre-mRNA is spliced efficiently, generating the expected intermediates (the 5' exon and the large lariats) and a 451-nt correctly spliced product (Fig. 4, lane 1) . Note that the splicing of long transcripts and the removal of long introns have been difficult to achieve in vitro. The high efficiency of the reaction seen here and in the following experiment is probably due to the improvement in the preparation of the nuclear splicing extracts. Splicing of IVS2705 pre-mRNA is also efficient and yields an additional spliced product 577 nt long as well as the expected 722-and 348-mer intermediates, resulting from the aberrant splicing pathway caused by the mutation (Fig. 4, lane 2) . The 1:2 ratio of correctly to incorrectly spliced RNAs is similar to that observed in vivo (24) . Oligonucleotide 3, spanning positions 573-589 of intron 2 ( Fig. 1) and complementary to the activated cryptic 3' splice site at nt 579, is very effective; it induces a dose-dependent reversal of splicing to the correct splicing pathway (Fig. 4, lanes 3-5) . There is a significant accumulation of the correctly spliced product at a 0.12 IAM concentration of the oligonucleotide (Fig. 4, lane 3) ; at 0.5 and 2 FM the restoration of correct splicing is virtually complete. Correct splicing is also completely restored at similar concentrations of oligonucleotide 4 (Fig. 1) , spanning positions 697-713 of the intron and targeted against the aberrant 5' splice site created by the mutation at nt 705 (Fig.  4, lanes 6-8) . At higher concentrations ofthis oligonucleotide (5 and 10 ,uM), correct splicing remains very efficient; however, at 20 uM, unspecific inhibition of splicing occurred. A control experiment, in which splicing ofIVS705 pre-mRNA is carried out in the presence of 5 ,uM oligonucleotide 1, shows no effect on the ratio of correctly to incorrectly spliced products (data not shown). This is further evidence of the high specificity of oligonucleotides used in these studies. The IVS2654 mutation (25) , frequently identified in thalassemic individuals ofChinese origin (16) , affects splicing via a mechanism analogous to that operating in the IVS705 mutant-i.e., by creating an additional 5' splice site at nt 653 and activating the common cryptic 3' splice site at nt 579 of intron 2. Splicing patterns of both mutated pre-mRNAs are presented side by side in Fig. 5 , lanes 1 and 2. Different lengths of incorrectly spliced products and of some of the intermediates reflect the different positions of aberrant 5' splice sites in IVS2654 and IVS705 mutants. The efficiency of aberrant splicing ofIVS2654 pre-mRNA is higher than that for IVS2705 pre-mRNA, and only small amounts of correctly spliced product, relative to the aberrant one, are detectable during splicing in vitro (Fig. 5, lane 2) . In spite of the high efficiency of aberrant splicing, oligonucleotide 3, targeted against the cryptic 3' splice site, as well as oligonucleotide 5, spanning nt 643-660 and targeted against the aberrant 5' splice site (Fig. 1) , restored correct splicing efficiently at concentrations similar to those used in the preceding experiment (Fig. 4) . At a 2 ,uM concentration of either oligonucleotide, the correctly spliced product accumulates, and the aberrant product is virtually undetectable (Fig. 5, lanes 7 and  11, respectively) .
The results presented in Figs. 4 three oligonucleotides are several times more effective than oligonucleotide 1 used in the experiments shown in Fig. 2 . The higher efficacy may be due to the fact that oligonucleotides 3-5 are 3 nt longerthan oligonucleotide 1 and may form more stable hybrids with RNA. They also block aberrant splice sites, allowing the splicing machinery to use the correct splice sites and, presumably, the correct branch point. In contrast, in (3110 pre-mRNA, oligonucleotide 1 forces the splicing machinery to use a suboptimal cryptic branch point sequence, which may result in relatively inefficient generation of correctly spliced mRNA.
In the experiments presented above, the oligonucleotides were added simultaneously with the other components ofthe splicing reaction. Prehybridization of the oligonucleotides with the pre-mRNA did not increase their efficiency, and oligonucleotides added 15 (21) (22) (23) . In other experiments they also affected splice site selection and/or efficiently inhibited pre-mRNA splicing (27) (10) and in genetic disorders, such as Tay-Sachs syndrome (30) , phenylketonuria (31) , and certain forms ofcystic fibrosis (32) , in which mutations leading to aberrant splicing of pre-mRNA have been identified. They may also promote reactivation ofcancer suppressor genes that are defective due to mutations affecting pre-mRNA splicing (33, 34) .
It is of interest that oligonucleotide 3 was able to inhibit aberrant splicing caused by two different mutations. There are a number of thalassemic mutations that lead to activation of a single cryptic splice site in exon 1 of the human f-globin gene (10); therefore, it seems likely that aberrant splicing could be corrected with a single oligonucleotide complementary to this site. This property would be very useful if an antisense approach were applied for therapeutic purposes.
The next logical step in this approach is to demonstrate that oligonucleotides can efficiently modify splicing pathways in vivo. A number of studies showed that transmembrane transport of oligonucleotides is possible and can be significantly improved by various modifications of these compounds, affecting their chemical properties (1) (2) (3) (4) . Splice sites have been shown to provide effective targets for inhibition ofgene expression by antisense oligonucleotides (35) (36) (37) . A recent report indicates that the use of a lipofection procedure dramatically increases delivery of the oligonucleotides to the cells and leads to their increased accumulation in the nucleus, the site of splicing (38) . These results suggest that the approach reported here will also be successful in vivo.
In this work the antisense oligonucleotides were used to generate correctly spliced mRNA from an aberrant premRNA substrate in vitro. It is important to note that oligonucleotides 1 and 3 were able to elicit a desired effect by antisense interaction at sequences distant from the actual mutations. These results point to the usefulness ofthe in vitro splicing system for rapid screening of suitable target sequences, thus narrowing down the number of oligonucleotides worthy of in vivo testing.
